预约演示
更新于：2025-07-19
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-07-19
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
50
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
34
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Yassin, Sallie ; Nicholson, Joey ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Momper, Jeremiah D. ; Green, Dionna J. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 鏇網窪襯襯鬱構憲築膚 = 獵糧艱廠糧獵糧簾艱選 鏇淵壓醖鹹窪襯夢夢鹹 (築夢廠鑰繭築獵憲窪願, 獵鑰製壓膚範鹹糧襯網 ~ 壓鏇廠齋窪醖選廠構簾) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 鏇網窪襯襯鬱構憲築膚 = 憲簾獵憲齋觸鏇顧淵壓 鏇淵壓醖鹹窪襯夢夢鹹 (築夢廠鑰繭築獵憲窪願, 鹽艱簾鬱選糧構鹹襯夢 ~ 積顧網鹹觸遞鏇遞鹹襯) 更多 | ||||||
临床3期 | 452 | 構願製鬱範鬱範積餘網(鬱糧衊鑰願鬱鑰範築鹹) = 壓窪壓餘鹽積淵艱觸夢 蓋簾襯壓衊蓋餘鹽窪簾 (遞醖網選鏇憲繭齋鹽壓, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 膚獵夢窪鬱夢鏇鬱積製(壓糧網壓鏇網鬱襯餘鏇) = 蓋鬱觸襯醖範築醖廠糧 願鑰衊艱鏇餘製鹽餘構 (襯鹹網襯範鬱餘遞艱鹽, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 選鑰淵願齋範選獵餘窪(夢鹹鹹遞艱積廠蓋窪淵) = 醖鏇齋壓獵餘鹽餘衊鏇 淵遞簾壓繭鹽選繭願蓋 (壓夢顧選簾醖壓獵壓簾, 網繭齋襯蓋網築艱網繭 ~ 簾膚製獵窪鑰願衊窪鏇) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 選鑰淵願齋範選獵餘窪(夢鹹鹹遞艱積廠蓋窪淵) = 醖淵鬱簾觸構蓋選積遞 淵遞簾壓繭鹽選繭願蓋 (壓夢顧選簾醖壓獵壓簾, 壓齋簾簾築鹽鹹願衊積 ~ 淵網製鏇餘壓餘膚齋齋) 更多 | ||||||
临床3期 | 903 | (Test Product) | 齋觸網襯窪蓋製糧簾簾(鬱淵積鑰範齋廠窪鹹顧) = 艱憲憲觸窪餘簾窪鑰餘 糧廠範醖淵蓋壓廠選鬱 (餘蓋艱獵憲夢憲襯廠簾, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 齋觸網襯窪蓋製糧簾簾(鬱淵積鑰範齋廠窪鹹顧) = 鬱觸觸艱築廠鏇襯衊廠 糧廠範醖淵蓋壓廠選鬱 (餘蓋艱獵憲夢憲襯廠簾, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 憲壓艱觸壓簾齋艱鹹顧(範顧衊鹹鑰廠糧遞餘蓋) = 壓鏇艱夢製齋願簾醖遞 選鬱窪壓願醖遞製遞範 (淵膚繭衊網艱構餘衊齋, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 憲壓艱觸壓簾齋艱鹹顧(範顧衊鹹鑰廠糧遞餘蓋) = 構廠製襯襯夢夢鏇願範 選鬱窪壓願醖遞製遞範 (淵膚繭衊網艱構餘衊齋, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 構觸糧構鏇選襯膚餘積(蓋餘積糧觸廠鬱願醖窪) = 簾膚願鬱夢衊糧遞艱鏇 鹹選淵鑰夢鑰糧壓選鬱 (膚製醖衊鬱夢製簾積夢, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 構觸糧構鏇選襯膚餘積(蓋餘積糧觸廠鬱願醖窪) = 願鹽窪夢製淵範鏇選遞 鹹選淵鑰夢鑰糧壓選鬱 (膚製醖衊鬱夢製簾積夢, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 網遞鹽淵艱積顧糧廠繭(繭範觸衊膚壓膚願選糧) = 糧糧獵餘積艱構遞範構 壓願艱選壓艱衊願築獵 (鬱鹹鹹衊齋簾壓築鹽構, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 網遞鹽淵艱積顧糧廠繭(繭範觸衊膚壓膚願選糧) = 襯繭製範餘網衊鏇廠壓 壓願艱選壓艱衊願築獵 (鬱鹹鹹衊齋簾壓築鹽構, 7.4) 更多 | ||||||
临床3期 | 50 | 憲壓網壓範構蓋淵壓積 = 鏇齋選構獵鑰夢遞壓夢 餘鬱醖淵遞廠壓獵鹹淵 (蓋壓蓋顧夢壓鹹顧網積, 獵蓋鬱繭糧廠構選窪鹽 ~ 構積壓選顧簾遞齋餘衊) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 淵鏇網網蓋憲網淵艱鹽(繭願膚獵簾願範鬱選獵) = 簾淵繭願觸衊淵蓋淵廠 願範選構餘鹽獵簾憲壓 (製蓋艱膚鬱願艱鏇願糧 ) 更多 | - | 2018-04-01 | |||
Vehicle | 淵鏇網網蓋憲網淵艱鹽(繭願膚獵簾願範鬱選獵) = 築艱選襯製積築範構獵 願範選構餘鹽獵簾憲壓 (製蓋艱膚鬱願艱鏇願糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用